PureTech Health PLC Sponsored ADR (NASDAQ:PRTC) Short Interest Down 39.6% in July

Key Points

• PureTech Health PLC's short interest decreased by 39.6% in July, falling from 5,300 shares to 3,200 shares.
• The company's stock is currently trading around $19.05, showing a 50-day moving average of $18.25 and a 1-year high of $25.00.
• Several hedge funds have recently increased their investments in PureTech Health, with a notable 39.2% increase in holdings by Pentwater Capital Management LP during the first quarter.

PureTech Health PLC Sponsored ADR (NASDAQ:PRTC - ) was the target of a large decline in short interest in July. As of July 31st, there was short interest totaling 3,200 shares, adeclineof39.6% from the July 15th total of 5,300 shares. Approximately0.0% of the company's stock are short sold. Based on an average daily volume of 3,500 shares, the days-to-cover ratio is currently 0.9 days. Based on an average daily volume of 3,500 shares, the days-to-cover ratio is currently 0.9 days. Approximately0.0% of the company's stock are short sold.

PureTech Health Price Performance

PRTC traded down $0.7920 during mid-day trading on Tuesday, reaching $19.0480. 1,136 shares of the stock were exchanged, compared to its average volume of 2,802. The company has a 50 day moving average price of $18.25 and a two-hundred day moving average price of $17.92. PureTech Health has a 1 year low of $13.30 and a 1 year high of $25.00.

Hedge Funds Weigh In On PureTech Health

A number of hedge funds have recently bought and sold shares of the company. Persistent Asset Partners Ltd purchased a new position in PureTech Health during the 2nd quarter worth $29,000. Diadema Partners LP purchased a new position in PureTech Health during the 2nd quarter worth $126,000. Pentwater Capital Management LP boosted its holdings in PureTech Health by 39.2% during the 1st quarter. Pentwater Capital Management LP now owns 33,560 shares of the company's stock worth $664,000 after acquiring an additional 9,449 shares during the last quarter. Finally, Millennium Management LLC purchased a new position in PureTech Health during the 4th quarter worth $823,000. 0.04% of the stock is owned by hedge funds and other institutional investors.

PureTech Health Company Profile

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.